- Home
- ABAT vs ADAP Comparison
ABAT vs ADAP Comparison
Compare ABAT & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- ADAP
- Stock Information
- Founded
- ABAT 2011
- ADAP 2008
- Country
- ABAT United States
- ADAP United Kingdom
- Employees
- ABAT N/A
- ADAP N/A
- Industry
- ABAT Metal Mining
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- ADAP Health Care
- Exchange
- ABAT Nasdaq
- ADAP Nasdaq
- Market Cap
- ABAT 87.2M
- ADAP 75.5M
- IPO Year
- ABAT N/A
- ADAP 2015
- Fundamental
- Price
- ABAT $1.41
- ADAP $0.28
- Analyst Decision
- ABAT
- ADAP Buy
- Analyst Count
- ABAT 0
- ADAP 6
- Target Price
- ABAT N/A
- ADAP $1.52
- AVG Volume (30 Days)
- ABAT 1.5M
- ADAP 1.6M
- Earning Date
- ABAT 05-16-2025
- ADAP 05-13-2025
- Dividend Yield
- ABAT N/A
- ADAP N/A
- EPS Growth
- ABAT N/A
- ADAP N/A
- EPS
- ABAT N/A
- ADAP N/A
- Revenue
- ABAT $1,857,877.00
- ADAP $179,639,000.00
- Revenue This Year
- ABAT $31,748.62
- ADAP N/A
- Revenue Next Year
- ABAT N/A
- ADAP $52.49
- P/E Ratio
- ABAT N/A
- ADAP N/A
- Revenue Growth
- ABAT N/A
- ADAP 878.53
- 52 Week Low
- ABAT $0.73
- ADAP $0.20
- 52 Week High
- ABAT $4.11
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- ABAT 54.09
- ADAP 49.68
- Support Level
- ABAT $1.29
- ADAP $0.26
- Resistance Level
- ABAT $1.42
- ADAP $0.30
- Average True Range (ATR)
- ABAT 0.12
- ADAP 0.03
- MACD
- ABAT -0.02
- ADAP 0.00
- Stochastic Oscillator
- ABAT 43.03
- ADAP 54.53
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.